Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion - PubMed (original) (raw)
Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion
James E Talmadge et al. Int Immunopharmacol. 2007 Feb.
Abstract
Selective inhibitors of cyclooxygenase-2 (COX-2) enzyme activity have shown chemopreventive activity in carcinogen-induced and transgenic rodent tumor models and clinically for colon cancer. However, the mechanism(s) by which COX-2 inhibitors reduce carcinogenesis remains controversial. We report herein that administration of the selective COX-2 inhibitor, celecoxib, significantly reduces the number of Gr1(+)CD11b(+) immature myeloid suppressor cells (IMSCs) during chemoprevention of 1,2-dimethylhydrazine diHCl-(1,2-DMH-) induction of large intestinal tumors in Swiss mice. Celecoxib administration also increased splenic lymphatic number and tumor infiltration by lymphocytes. The 1,2-DMH induction of large intestinal tumors was associated with a four-fold increase in IMSCs, and a decrease in splenic T cell number and function. Concordant with the changes in the IMSC frequency, messenger ribonucleic acid (mRNA) levels of inducible nitric oxide synthase (NOS-2) and arginase (Arg) were increased in the spleen of the tumor-bearing mice and normalized by celecoxib administration. In addition to delaying tumor induction, reducing tumor number, and increasing lymphocyte infiltration of tumors, celecoxib therapy reversed CD4(+) T cell loss, decreased IMSC numbers and increased mRNA levels of NOS-2 and Arg in the spleen. In summary, our results suggest that celecoxib chemoprevention of autochthonous intestinal tumors can regulate IMSCs and CD4(+) T cell numbers.
Similar articles
- Prevention of tumors of the large intestine by celecoxib in mice.
Coles M, Toth B. Coles M, et al. In Vivo. 2005 Jul-Aug;19(4):661-5. In Vivo. 2005. PMID: 15999531 - Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.
Donkor MK, Lahue E, Hoke TA, Shafer LR, Coskun U, Solheim JC, Gulen D, Bishay J, Talmadge JE. Donkor MK, et al. Int Immunopharmacol. 2009 Jul;9(7-8):937-48. doi: 10.1016/j.intimp.2009.03.021. Epub 2009 Apr 9. Int Immunopharmacol. 2009. PMID: 19362167 - Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
Kismet K, Akay MT, Abbasoglu O, Ercan A. Kismet K, et al. Cancer Detect Prev. 2004;28(2):127-42. doi: 10.1016/j.cdp.2003.12.005. Cancer Detect Prev. 2004. PMID: 15068837 Review. - [COX-2 inhibitors in cancer prevention].
Grau de Castro JJ. Grau de Castro JJ. Rev Clin Esp. 2005 Sep;205(9):446-56. doi: 10.1157/13079075. Rev Clin Esp. 2005. PMID: 16194481 Review. Spanish.
Cited by
- Myeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets.
Al-Mterin MA, Elkord E. Al-Mterin MA, et al. Explor Target Antitumor Ther. 2022;3(4):497-510. doi: 10.37349/etat.2022.00097. Epub 2022 Aug 31. Explor Target Antitumor Ther. 2022. PMID: 36081407 Free PMC article. Review. - Candida/Staphylococcal Polymicrobial Intra-Abdominal Infection: Pathogenesis and Perspectives for a Novel Form of Trained Innate Immunity.
Esher SK, Fidel PL Jr, Noverr MC. Esher SK, et al. J Fungi (Basel). 2019 May 9;5(2):37. doi: 10.3390/jof5020037. J Fungi (Basel). 2019. PMID: 31075836 Free PMC article. Review. - Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice.
Abe F, Dafferner AJ, Donkor M, Westphal SN, Scholar EM, Solheim JC, Singh RK, Hoke TA, Talmadge JE. Abe F, et al. Cancer Immunol Immunother. 2010 Jan;59(1):47-62. doi: 10.1007/s00262-009-0719-2. Epub 2009 May 18. Cancer Immunol Immunother. 2010. PMID: 19449184 Free PMC article. - Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression.
Awad RM, De Vlaeminck Y, Maebe J, Goyvaerts C, Breckpot K. Awad RM, et al. Front Immunol. 2018 Aug 31;9:1977. doi: 10.3389/fimmu.2018.01977. eCollection 2018. Front Immunol. 2018. PMID: 30233579 Free PMC article. Review. - Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.
Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Diaz-Montero CM, et al. Cancer Immunol Immunother. 2009 Jan;58(1):49-59. doi: 10.1007/s00262-008-0523-4. Epub 2008 Apr 30. Cancer Immunol Immunother. 2009. PMID: 18446337 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials